ホーム>>Signaling Pathways>> Microbiology & Virology>> HSV>>BRL44385

BRL44385

カタログ番号GC32371

BRL44385 は、単純ヘルペス ウイルス 1 型および 2 型 (HSV-1 および HSV2)、水痘帯状疱疹ウイルス (VZV)、エプスタイン-バーウイルス (EBV) の複製を強力かつ選択的に阻害します。

Products are for research use only. Not for human use. We do not sell to patients.

BRL44385 化学構造

Cas No.: 114778-60-8

サイズ 価格 在庫数 個数
1mg
$937.00
在庫あり
5mg
$1,866.00
在庫あり
10mg
$3,171.00
在庫あり
20mg
$5,598.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

BRL44385 is a potent and selective inhibitor of the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV2), varicella zoster virus (VZV) and Epstein-Barr virus (EBV).

BRL44385 is a selective antiherpesvirus agent. Following oral administration, BRL 55792 is very well absorbed and provides high and prolonged concentrations of BRL44385 in the blood. In mice 15 min and 60 min after administration of a single oral dose of BRL 55792, the concentrations of BRL44385 in the blood are considerably higher than those obtain after oral administration of either BRL44385 or BRL46720 and the bioavailability of BRL 44385 from oral BRL 55792 is 66% of that achieves with the same dose of the sodium salt of BRL44385 administered intravenously[1].

[1]. M. R. Harnden, et al. Synthesis, oral bioavailability and in vivo activity of acetal derivatives of the selective antiherpesvirus agent 9-(3-hydroxypropoxy) guanine (SRL 44385). Antiviral Chemistry & Chemotherapy (1994) 5(3), 147-154.

レビュー

Review for BRL44385

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BRL44385

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.